| Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317) |
|---|
| 05/10/2002 | WO2002036554A2 Amidino-urea serotonin receptor ligands and compositions, their pharmaceutical uses, and methods for their snythesis |
| 05/10/2002 | WO2002036553A2 Substituted alkanoic acids |
| 05/10/2002 | WO2002036551A1 Peptide derivatives and their pharmaceutically acceptable salts, processes for preparation of both, and use thereof |
| 05/10/2002 | WO2002036547A1 Cyclopropanecarboxylic acid amide compounds and medicinal use thereof |
| 05/10/2002 | WO2002036542A1 Crystalline forms of venlafaxine hydrochloride |
| 05/10/2002 | WO2002036171A1 Methods for enhancing the efficacy of cytotoxic agents through the use of hsp90 inhibitors |
| 05/10/2002 | WO2002036162A2 Compositions for treatment of ocular neovascularization and neural injury |
| 05/10/2002 | WO2002036157A1 Use of melagatran for manufacture of a medicament for the treatment of ischemic disorders |
| 05/10/2002 | WO2002036155A1 Use of blood coagulation factor xiii for treating haemophilia a |
| 05/10/2002 | WO2002036154A2 Procollagen (iii) propeptides and related substances for treating fibrotic diseases |
| 05/10/2002 | WO2002036150A1 Gene-digesting gene and enzyme having vaccine-like effect |
| 05/10/2002 | WO2002036149A2 Methods for obtaining inhibitors of t-cell membrane protein (tirc7) ligand binding and uses thereof |
| 05/10/2002 | WO2002036135A2 Compositions for antitumour treatment containing ecteinascidin 743 |
| 05/10/2002 | WO2002036131A1 In vivo stimulation of angiogenic activity |
| 05/10/2002 | WO2002036116A2 Tripeptidyl peptidase inhibitors |
| 05/10/2002 | WO2002036115A1 Sulphonamides for the treatment of central nervous system diseases |
| 05/10/2002 | WO2002036110A2 Oral self-emulsifying formulations of pyranone protease inhibitors |
| 05/10/2002 | WO2002036108A2 Use of 20-hete synthesizing enzyme inhibitors as therapy for cerebral vascular diseases |
| 05/10/2002 | WO2002036107A2 Treatment of motor fluctuations with 5-hydroxytryptamine 1a receptor activity enhancing coumpounds |
| 05/10/2002 | WO2002036106A2 Novel medicament compositions based on anticholinergics and corticosteroids |
| 05/10/2002 | WO2002036097A2 Delivery system for entrapping charged macromolecules and a method for preparing same |
| 05/10/2002 | WO2002036075A2 Small molecule compositions for binding to hsp90 |
| 05/10/2002 | WO2002036073A2 Receptor antagonist-lipid conjugates and delivery vehicles containing same |
| 05/10/2002 | WO2002036072A2 Method for short-term and long-term drug dosimetry |
| 05/10/2002 | WO2002035942A1 Food grade transglutaminase inhibitor and uses thereof |
| 05/10/2002 | WO2002022600A3 Chemokine receptor binding heterocyclic compounds |
| 05/10/2002 | WO2002016381A3 Composition and method for inhibiting platelet aggregation |
| 05/10/2002 | WO2002012238A3 2-(4-PYRIDYL)AMINO-6-DIALKOXYPHENYL-PYRIDO[2,3-d]PYRIMIDIN-7-ONES |
| 05/10/2002 | WO2002008200A3 Arylethene-sulfonamides, their preparation and their use as endothelin antagonists |
| 05/10/2002 | WO2001089564A3 Methods for diagnosing and treating hemostatic disorders by modulating p-selectin activity |
| 05/10/2002 | WO2001089282A3 2-amino-3-hydroxy-4-tert-leucyl-amino-5-phenyl-pentanoic acid amide derivatives |
| 05/10/2002 | WO2001088116A3 Method of modulating activation of lymphocytes via modulation of pituitary tumor transforming gene, related screeining methods |
| 05/10/2002 | WO2001085993A3 Method for detecting growth hormone variations in humans, the variations and their uses |
| 05/10/2002 | WO2001083711A3 Clearance of ras-mediated neoplastic cells from mixed cellular compositions using reovirus |
| 05/10/2002 | WO2001081342A3 Novel epothilone derivatives, method for the preparation thereof and their pharmaceutical use |
| 05/10/2002 | WO2001079288A3 Cytokine uses; compositions; methods |
| 05/10/2002 | WO2001077145A3 Integrin binding peptide derivatives |
| 05/10/2002 | WO2001072288A3 Use of cdp-choline for the treatment of alcohol withdrawal syndrome |
| 05/10/2002 | WO2001070808A3 Angiogenesis - associated proteins, and nucleic acids encoding the same |
| 05/10/2002 | WO2001070706A3 4-oxo-1,4-dihydro-3-cinnolinecarboxamides as antiviral agents |
| 05/10/2002 | WO2001068697A3 Methods and compositions for immunoregulation |
| 05/10/2002 | WO2001068135A3 Compositions and methods for affecting osteogenesis |
| 05/10/2002 | WO2001068034B1 1, 2, 4-triazoloribonucleoside prodrugs and their administration to treat viral disease conditions |
| 05/10/2002 | WO2001066594A3 Human protein kinases and protein kinase-like enzymes |
| 05/10/2002 | WO2001064650A3 Synthesis of epothilones, intermediates thereto and analogues thereof |
| 05/10/2002 | WO2001064251A3 Combination chemotherapy |
| 05/10/2002 | WO2001064236A3 METHODS FOR TREATING FSH RELATED CONDITIONS WITH GnRH ANTAGONISTS |
| 05/10/2002 | WO2001064214A3 Compositions and methods for the treatment of inflammatory diseases using topoisomerase inhibitors |
| 05/10/2002 | WO2001062779A3 New transcription factor carp-2 |
| 05/10/2002 | WO2001046455A3 Survivin promotion of angiogenesis |
| 05/10/2002 | WO2001046198A3 Nonpeptide kappa opioid receptor antagonists |
| 05/10/2002 | WO2001041780A3 Use of an immunosuppressant for increasing an antifugal activity of a lipopeptide |
| 05/10/2002 | WO2001041768A3 Use of hymenialdisine or derivatives thereof in the manufacture of medicaments |
| 05/10/2002 | WO2001038326A3 Imidazo-pyridine derivatives as ligands for gaba receptors |
| 05/10/2002 | WO2001038324A3 Imidazole derivatives and their use as raf kinase inhibitors |
| 05/10/2002 | WO2001036638A3 Polypeptides and nucleic acids encoding same |
| 05/10/2002 | WO2001034600A9 Protease inhibitors |
| 05/10/2002 | WO2001034599A9 Protease inhibitors |
| 05/10/2002 | WO2001034157A9 Protease inhibitors |
| 05/10/2002 | WO2001034117A9 A method for chemoprevention of prostate cancer |
| 05/10/2002 | WO2001032155A3 Use of egfr tyrosine kinase inhibitors for treating breast cancer |
| 05/10/2002 | WO2001031007A9 Nucleic acid molecules derived from rat brain and programmed cell death models |
| 05/10/2002 | WO2001029036A3 Allosteric sites on muscarinic receptors |
| 05/10/2002 | WO2001028545A3 Use of carbon monoxide dependent guanylyl cyclase modifiers to stimulate neuritogenesis |
| 05/10/2002 | WO2001027146A9 Chemokine receptor |
| 05/10/2002 | WO2001027135A3 Regulators of the hedgehog pathway, compositions and uses related thereto |
| 05/10/2002 | WO2001026629A3 Neutral-cationic lipid for nucleic acid and drug delivery |
| 05/10/2002 | WO2001026618A3 Composition, especially a cosmetic composition, containing a steroid and a liposoluble uv filter |
| 05/10/2002 | WO2001024827A3 INHIBITORS OF THE ENDOTHELIN SIGNALLING PATHWAY AND αVβ3 INTEGRIN RECEPTOR ANTAGONISTS FOR COMBINATION THERAPY |
| 05/10/2002 | WO2001024784A3 New use |
| 05/10/2002 | WO2001023389A3 Certain alkylene diamine-substituted heterocycles |
| 05/10/2002 | WO2001023386A3 Benzodiazepin derivatives, the production and use thereof |
| 05/10/2002 | WO2001005388A3 Use of a fatty derivative for the treatment of external secretiondisorders |
| 05/10/2002 | WO2000067736A3 Therapeutic use of an inhibitor or an antagonist of an abc protein in bone |
| 05/10/2002 | WO2000042208A8 Adenovirus vectors, packaging cell lines, compositions, and methods for preparation and use |
| 05/10/2002 | CA2431641A1 Treatment of motor fluctuations |
| 05/10/2002 | CA2428012A1 Use of melagatran for manufacture of a medicament for the treatment of ischemic disorders |
| 05/10/2002 | CA2427802A1 Methods and compositions for the diagnosis of cancer susceptibilites and defective dna repair mechanisms and treatment thereof |
| 05/10/2002 | CA2427629A1 Gene regulation therapy involving ferritin |
| 05/10/2002 | CA2427613A1 (7-(3-carboxyphenyl)-4-chloroisoquinolin-1-yl)guanidine |
| 05/10/2002 | CA2427589A1 Indolylpiperidine derivatives as antihistaminic and antiallergic agents |
| 05/10/2002 | CA2427572A1 Immunomodulatory peptides derived from heat shock proteins and uses thereof |
| 05/10/2002 | CA2427568A1 Tricyclic derivatives of indole with antiangiogenic activity |
| 05/10/2002 | CA2427565A1 Bis-heterocyclic compounds with antitumour and chemosensitising activity |
| 05/10/2002 | CA2427557A1 Use of 20-hete synthesizing enzyme inhibitors as therapy for cerebral vascular diseases |
| 05/10/2002 | CA2427535A1 Use of blood coagulation factor xiii for treating haemophilia a |
| 05/10/2002 | CA2427518A1 Polynucleotide encoding an activated human t-lymphocyte-derived protein related to ubiquitin conjugating enzyme |
| 05/10/2002 | CA2427394A1 3-oxadiazol-5-yl-1-aminoalkyl-1h-indole derivatives |
| 05/10/2002 | CA2427267A1 Membrane fractions of 1,2-sn-diacylglycerol-enriched cells |
| 05/10/2002 | CA2427257A1 Expression vectors able to elicit improved immune response and methods of using same |
| 05/10/2002 | CA2427194A1 Method for short-term and long-term drug dosimetry |
| 05/10/2002 | CA2427193A1 Food grade transglutaminase inhibitor and uses thereof |
| 05/10/2002 | CA2426987A1 Human cord blood derived unrestricted somatic stem cells (ussc) |
| 05/10/2002 | CA2426977A1 Sulphonamides for the treatment of central nervous system diseases |
| 05/10/2002 | CA2426967A1 Delivery system for entrapping charged macromolecules and a method for preparing same |
| 05/10/2002 | CA2426762A1 Methods for enhancing the efficacy of cytotoxic agents through the use of hsp90 inhibitors |
| 05/10/2002 | CA2426658A1 Methods of diagnosing, preventing and treating neurological disorders and neuronal injuries |
| 05/10/2002 | CA2426395A1 Crystalline forms of fluvastatin sodium |
| 05/10/2002 | CA2426047A1 Therapeutic oligonucleotides of reduced toxicity |
| 05/10/2002 | CA2425583A1 Methods for obtaining inhibitors of tirc7 ligand binding and uses thereof |